NEU neuren pharmaceuticals limited

0.80%

$12.54

Ann: 2023 Annual Report to shareholders, page-80

First 80 Last

Share
Profile

Follow
reggie78

2,170 Posts.

572

25/04/24

11:29

Post #: 73509546
Share

Originally posted by Kjt1969: ↑

I think hottod is right that 1) pursuing a Ph III PMS alone would be risky (requiring most of their existing cash and income) and 2) that partnering for PMS or licensing it out would muddy the waters for a future T/O (a large acquirer would prefer an asset not already encumbered to other parties).

However, as others have mentioned, there's still the 3rd way, external funding from a party like Blackrock. This would allow Neuren to access much more cash (several Ph 3s? lots more Ph 2s?), reduce the risks, and also avoid complications for an eventual T/O. The assumption would be that the funding party would be along for the T/O and cooperate with it. In fact, it would be the reason they're involved - their goal is a full 'exit' in a few years.

This move would dilute the eventual return with the 3rd party obviously getting a % of any final deal for their support. However, so long as you can see how giving up 15-25% equity (or agreeing to the funding party taking a similarly structured 'fee' in a T/O) now would help you increase the final T/O price by at least this 15-25% (something likely easy to argue for) then this could be an easy decision.

Funding is normally expensive. However, Neuren's in a great position with an on-market product, strong pipeline, positive cashflows and likely a relatively short time frame to exit (maybe 2-3 years, unlike a biotech startup with an exit 10 years away). Neuren would be able to drive a deal on favourable terms. In fact, I could imagine parties like Blackrock falling over themselves to assist in funding such a high quality opportunity.

As we know, there's already been a few comments from Jon & others hinting that such an arrangement may be under consideration.

Expand

I think that is exactly the play.

By exploring that partner option as you note 15-25% share with a Blackstone or alike not only tells any potential suitors now that they indeed need to pay up at least the US $5bn -$10bn figure or US $20bn+ in a couple years time when we have advanced further with our partner…

I know the TO crew for $50 with their blinkers on may not like it but this is the ultimate scenario to extract maximum value.

NEU Price at posting: $18.85 Sentiment: Buy Disclosure: Held
12 Upvote

0 Great analysis

Reply

Top Stories

NVO

Novo flags antimony and gold in the Pilbara – but does it need to step back?

PIQ

Proteomics notches up as company launches PromarkerD into the US

HotCopper Highlights for Week 25: 4DS Memory, Meeka & Sprott-citement

Week 25 Wrap: Fed & BoE pause rates ahead of RBA; Santos-ADNOC, Oz tax reforms

ASX Market Open: Stocks slide as Trump tosses up attacking Iran directly | June 20

Friday’s HotCopper trends: Dreadnoughts's drill delight, Galan's beaut raise | June 19

Thursday's HotCopper trends: Second Amplia response, Race combo dosing | June 19

PV1

Hydrogen tanker stock Provaris inks MOU with "K" LINE to provide advice

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

AL3

AML3D opens new facility in Ohio as US Defence strategy bears fruit

First 80 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $12.54		Change 0.100(0.80%)		Mkt cap ! $1.559B

Open	High	Low	Value	Volume
$12.44	$12.73	$12.13	$11.07M	885.6K

Buyers (Bids)

No.	Vol.	Price($)
1	1215	$12.52

Sellers (Offers)

Price($)	Vol.	No.
$12.54	804	1

View Market Depth

No.	Vol.	Price($)
1	400	12.480
1	796	12.300
1	400	12.240
1	3000	12.230
1	761	12.210

Price($)	Vol.	No.
12.600	1020	1
12.710	628	2
12.720	1982	1
12.820	3050	1
12.900	5012	1

Last trade - 16.10pm 20/06/2025 (20 minute delay)

NEU (ASX) Chart

Ann: 2023 Annual Report to shareholders, page-80

Novo flags antimony and gold in the Pilbara – but does it need to step back?

Proteomics notches up as company launches PromarkerD into the US

HotCopper Highlights for Week 25: 4DS Memory, Meeka & Sprott-citement

Week 25 Wrap: Fed & BoE pause rates ahead of RBA; Santos-ADNOC, Oz tax reforms

ASX Market Open: Stocks slide as Trump tosses up attacking Iran directly | June 20

Friday’s HotCopper trends: Dreadnoughts's drill delight, Galan's beaut raise | June 19

Thursday's HotCopper trends: Second Amplia response, Race combo dosing | June 19

Hydrogen tanker stock Provaris inks MOU with "K" LINE to provide advice

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

AML3D opens new facility in Ohio as US Defence strategy bears fruit

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: 2023 Annual Report to shareholders, page-80

Top Stories

Novo flags antimony and gold in the Pilbara – but does it need to step back?

Proteomics notches up as company launches PromarkerD into the US

HotCopper Highlights for Week 25: 4DS Memory, Meeka & Sprott-citement

Week 25 Wrap: Fed & BoE pause rates ahead of RBA; Santos-ADNOC, Oz tax reforms

ASX Market Open: Stocks slide as Trump tosses up attacking Iran directly | June 20

Friday’s HotCopper trends: Dreadnoughts's drill delight, Galan's beaut raise | June 19

Thursday's HotCopper trends: Second Amplia response, Race combo dosing | June 19

Hydrogen tanker stock Provaris inks MOU with "K" LINE to provide advice

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

AML3D opens new facility in Ohio as US Defence strategy bears fruit

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News